Natera (NTRA) Stock Forecast, Price & News

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Natera in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" NTRA shares.
View NTRA analyst ratings or view top-rated stocks.

5 equities research analysts have issued 12-month price objectives for Natera's shares. Their NTRA share price forecasts range from $66.00 to $100.00. On average, they expect the company's stock price to reach $73.78 in the next twelve months. This suggests a possible upside of 52.9% from the stock's current price.
View analysts price targets for NTRA or view top-rated stocks among Wall Street analysts.

Natera's stock was trading at $40.17 on January 1st, 2023. Since then, NTRA stock has increased by 20.1% and is now trading at $48.25.
View the best growth stocks for 2023 here.

Natera saw a increase in short interest during the month of May. As of May 15th, there was short interest totaling 6,740,000 shares, an increase of 17.2% from the April 30th total of 5,750,000 shares. Based on an average daily volume of 1,290,000 shares, the short-interest ratio is currently 5.2 days.
View Natera's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023.
View our NTRA earnings forecast.

Natera, Inc. (NASDAQ:NTRA) posted its earnings results on Tuesday, May, 9th. The medical research company reported ($1.23) earnings per share for the quarter, missing the consensus estimate of ($1.18) by $0.05. The medical research company had revenue of $241.76 million for the quarter, compared to analysts' expectations of $227.43 million. Natera had a negative trailing twelve-month return on equity of 101.02% and a negative net margin of 62.93%. The business's revenue for the quarter was up 24.5% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($1.45) earnings per share.

ETFs with the largest weight of Natera (NASDAQ:NTRA) stock in their portfolio include Global X Genomics & Biotechnology ETF (GNOM), Alger Mid Cap 40 ETF (FRTY), Alger 35 ETF (ATFV), First Trust Nasdaq Lux Digital Health Solutions ETF (EKG), Invesco DWA Healthcare Momentum ETF (PTH), ROBO Global Healthcare Technology and Innovation ETF (HTEC), Principal Healthcare Innovators ETF (BTEC) and VanEck Biotech ETF (BBH).

Natera issued an update on its FY 2023 earnings guidance on Tuesday, May, 9th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $995.00M-$1.01 billion, compared to the consensus revenue estimate of $990.72 million.

158 employees have rated Natera Chief Executive Officer Steve Chapman on Glassdoor.com. Steve Chapman has an approval rating of 91% among the company's employees. This puts Steve Chapman in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Natera investors own include CA (CA), BlackRock (BLK), Endologix (ELGX), Chipotle Mexican Grill (CMG), Athabasca Oil (ATH), NIC (EGOV), Aegean Marine Petroleum Network (ANW), Micron Technology (MU), Transocean (RIG) and Allergan (AGN).

(NTRA) raised $101 million in an initial public offering (IPO) on Thursday, July 2nd 2015. The company issued 6,300,000 shares at $15.00-$17.00 per share. Morgan Stanle, Cowen and Company and Piper Jaffray served as the underwriters for the IPO and Baird and Wedbush Pacgrow were co-managers.

Natera trades on the NASDAQ under the ticker symbol "NTRA."

Natera's stock is owned by many different retail and institutional investors. Top institutional investors include Fred Alger Management LLC (6.84%), State Street Corp (2.40%), Samlyn Capital LLC (2.30%), RTW Investments LP (2.28%), Principal Financial Group Inc. (1.67%) and Geode Capital Management LLC (1.34%). Insiders that own company stock include Daniel Rabinowitz, Gail Boxer Marcus, Herm Rosenman, James Healy, Jonathan Sheena, Matthew Rabinowitz, Michael Burkes Brophy, Patrick J Donovan, Robert Alan Schueren, Roelof Botha, Rowan E Chapman, Roy D Baynes, Steven Leonard Chapman, Todd C Cozzens and Todd C Cozzens.
View institutional ownership trends.

Shares of NTRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of NTRA stock can currently be purchased for approximately $48.25.

Natera (NASDAQ:NTRA) has a market capitalization of $5.51 billion and generates $820.22 million in revenue each year. The medical research company earns $-547,800,000.00 in net income (profit) each year or ($5.35) on an earnings per share basis.

The company employs 3,018 workers across the globe.

Natera's mailing address is 201 INDUSTRIAL ROAD SUITE 410, SAN CARLOS CA, 94070. The official website for the company is www.natera.com. The medical research company can be reached via phone at (650) 249-9090 or via email at mbrophy@natera.com.